Parallax Volatility Advisers’s TG Therapeutics TGTX Stock Holding History

Parallax Volatility Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100	Closed	-$836	–	2489
2023 Q3	$836	Hold	100	–	–	﹤0.01%	2210
2023 Q2	$2.48K	Buy	+100	New	+$2.58K	﹤0.01%	2262
2022 Q3	–	Sell	-7,900	Closed	-$33K	–	3354
2022 Q2	$33K	Buy	+7,900	New	+$49.3K	﹤0.01%	2531
2022 Q1	–	Sell	-53,900	Closed	-$1.02M	–	3174
2021 Q4	$1.02M	Sell	53,900 -98,200	-65%	-$2.55M	﹤0.01%	1259
2021 Q3	$5.06M	Buy	152,100 +10,500	+7%	+$325K	﹤0.01%	834
2021 Q2	$5.49M	Buy	141,600 +48,100	+51%	+$1.89M	0.01%	631
2021 Q1	$4.51M	Buy	+93,500	New	+$4.49M	0.01%	534
2020 Q1	–	Sell	-50,000	Closed	-$555K	–	2714
2019 Q4	$555K	Hold	50,000	–	–	﹤0.01%	1703
2019 Q3	$281K	Hold	50,000	–	–	﹤0.01%	1762
2019 Q2	$433K	Hold	50,000	–	–	﹤0.01%	1548
2019 Q1	$402K	Buy	+50,000	New	+$270K	﹤0.01%	1610
2018 Q4	–	Sell	-75,000	Closed	-$420K	–	3931
2018 Q3	$420K	Hold	75,000	–	–	﹤0.01%	1474
2018 Q2	$986K	Buy	+75,000	New	+$1.03M	﹤0.01%	1099

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Parallax Volatility Advisers's TGTX Position: Q3 2023 in Review

Parallax Volatility Advisers sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 22,303 shares — an estimated $311K sold.

Parallax Volatility Advisers first reported a position in TGTX in Q4 2015 and held it in 12 quarters. The position peaked at $1.49M in Q3 2021. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

Parallax Volatility Advisers reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 22,303 TG Therapeutics shares in Q3 2023, an estimated $311K.
Parallax Volatility Advisers first reported a position in TG Therapeutics in Q4 2015 and held it in 12 quarters.
Parallax Volatility Advisers's TG Therapeutics position peaked at $1.49M in Q3 2021.
236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Parallax Volatility Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.